Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$ABBV {{ '2017-06-12T11:26:02+0000' | timeago}} • Announcement

$ABBV will present data from multiple clinical trials evaluating its leukaemia drug venetoclax at the 22nd European Hematology Association Annual Congress to be held in Madrid. Data will be presented from 15 studies across common hematologic malignancies, including chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

$ABBV {{ '2018-01-29T15:39:15+0000' | timeago}} • Webcast

$ABBV expects 1Q18 adjusted EPS of $1.77-1.79 excluding about $0.31 as specified items. $ABBV anticipates 1Q18 operational revenue growth approaching the mid-teens. Holding exchange rates constant at current levels, the company would expect foreign exchange to have a favorable impact on reported sales growth of 3% in 1Q18.

$ABBV {{ '2018-01-29T15:35:39+0000' | timeago}} • Webcast

On the topline in 2018, $ABBV expects revenue approaching $32Bil, which reflects favorable impact from foreign currency of roughly 1.5%. Included in this are the assumptions for the company's key products. Humira will maintain its strong position as the front-line therapy across therapeutic segments and continues to be an important growth driver.

$ABBV {{ '2018-01-29T15:26:22+0000' | timeago}} • Webcast

$ABBV's ongoing Phase 3 studies in small-cell lung cancer also continue to advance, with the Tahoe study in second-line setting and the Meru trial in front-line patients both now well underway. $ABBV is also evaluating Rova-T with Opdivo and with Opdivo and Yervoy in mid-stage combination study with potential to start seeing data later in the year.

$ABBV {{ '2018-01-29T15:23:26+0000' | timeago}} • Webcast

This year, $ABBV will launch major label expansion for Vebclexta in relapsed/refractory cancer type chronic lymphocytic leukemia as well as elagolix in endometriosis. Endometriosis is painful disorder in which tissue that normally lines inside of uterus grows outside.

$ABBV {{ '2018-01-29T15:14:01+0000' | timeago}} • Webcast

In 2018, $ABBV plans to accelerate pension funding by $750MM as well as enhancing non-executive employee compensation. $ABBV is also planning one-time shareable contribution of about $350MM to select not-for-profit organizations, supporting initiatives such as the Puerto Rico rebuilding efforts, children's healthcare access programs, and charities.

$ABBV {{ '2018-01-26T15:15:38+0000' | timeago}} • Announcement

Over next 5 years, $ABBV plans to invest about $2.5Bil in capital projects in the U.S. and the company is currently evaluating additional expansion of its U.S. facilities. The company also plans to accelerate pension funding by $750MM, as well as enhance non-executive employee compensation.

$ABBV {{ '2018-01-26T15:12:51+0000' | timeago}} • Announcement

$ABBV expects FY18 EPS of $6.45-6.55. The company lifted its 2018 adjusted EPS guidance to $7.33-7.43 from $6.37-6.57, to reflect the impact of U.S. tax reform and stronger operating performance. $ABBV sees adjusted effective tax rate to increase to 13% over next 5 years as a result of increased domestic income and investment.

$ABBV {{ '2018-01-26T15:01:09+0000' | timeago}} • Announcement

$ABBV reported a drop in 4Q17 earnings due to about $4.5Bil of tax charge arising from enactment of the Tax Cuts and Jobs Act. Net income fell to $52MM or $0.03 per share from $1.4Bil or $0.85 per share last year. Net revenue grew 14% to $7.74Bil. Adjusted EPS increased 23.3% to $1.48.

$ABBV {{ '2018-01-26T14:34:56+0000' | timeago}} • Infographic

$ABBV AbbVie Inc. Earnings AlphaGraphic: Q4 2017 Highlights

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$ABBV {{ '2017-12-04T15:31:15+0000' | timeago}} • Announcement

$ABBV announced that Risankizumab met all co-primary and ranked secondary endpoints in Phase 3 study. Risankizumab is used in the treatment of patients with moderate to severe plaque psoriasis.

$ENTA {{ '2017-11-20T21:52:37+0000' | timeago}} • Announcement

Biotech company $ENTA swung to 4Q17 profit on higher revenue, driven by milestone payments totaling $65MM received following $ABBV's U.S. approval of MAVYRET and EU approval of MAVIRET. Net income was $36.5MM or $1.86 per share in the quarter compared to a net loss of $1.8MM, or $0.09 loss per share a year earlier. Revenue jumped to $75.9MM.

$ABBV {{ '2017-10-27T19:44:43+0000' | timeago}} • Webcast

As $ABBV posted 3Q17 results, it now sees full-year gross margin as a percentage of sales at 80.5% and operating margin at 42.5%. AbbVie also expects full-year net interest expense of approximately $1Bil with an adjusted tax rate of about 19%.

$ABBV {{ '2017-10-27T16:20:17+0000' | timeago}} • Infographic

$ABBV AbbVie, Inc. Earnings AlphaGraphic: Q3 2017 highlights

$ABBV {{ '2017-10-27T12:14:02+0000' | timeago}} • Announcement

$ABBV, as it posted 3Q17 results, declared an 11% hike in the quarterly cash dividend to $0.71 per share, beginning with the dividend payable on Feb. 15, 2018 to shareholders of record as of Jan. 12, 2018.

$ABBV {{ '2017-10-27T12:12:54+0000' | timeago}} • Announcement

As $ABBV posted 3Q17 results, it updated its GAAP diluted EPS guidance for FY17 to $4.27-4.29. AbbVie now expects to deliver adjusted diluted EPS for the full year of $5.53-5.55. The drug giant now sees global HUMIRA sales to approach $21Bil in 2020.

$ABBV {{ '2017-10-27T12:11:23+0000' | timeago}} • Announcement

With worldwide net revenues jumping 8.8% to about $7.0Bil in 3Q17, $ABBV saw net earnings inch up 2% to $1.6Bil or $1.01 per diluted share. Global HUMIRA sales saw a 15% hike while global IMBRUVICA net revenues surged 37% in the quarter.

$ABBV {{ '2017-10-18T16:05:30+0000' | timeago}} • Announcement

$ABBV and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced that they have entered an immuno-oncology research collaboration.

$ABBV {{ '2017-09-27T12:14:25+0000' | timeago}} • Announcement

$ABBV announced that the Japanese Ministry of Health, Labor and Welfare has approved MAVIRET, a once-daily, treatment for adults with chronic hepatitis C virus infection. The treatment was also recently granted marketing authorization by the European Commission and approved by the US FDA.

$ABBV {{ '2017-09-22T11:48:04+0000' | timeago}} • Announcement

$ABBV and $BMY announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC).

Recent Transcripts
SYN | Earnings
February 22nd 2018, 1:30pm
TXMD | Earnings
February 20th 2018, 9:30pm
MDT | Earnings
February 20th 2018, 1:00pm
ACOR | Earnings
February 15th 2018, 1:30pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
SYN | Earnings
February 22nd 2018, 1:30pm
TXMD | Earnings
February 20th 2018, 9:30pm
MDT | Earnings
February 20th 2018, 1:00pm
ACOR | Earnings
February 15th 2018, 1:30pm
AlphaGraphics you may like